Colonial High Income Muni Trust (CXE) 5.49 $CXE MFS

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Colonial High Income Muni Trust (CXE) 5.49 $CXE

MFS Announces Closed-End Fund Distributions
BusinessWire - Wed Jun 01, 3:30PM CDT
MFS Investment Management(R) (MFS(R)) announced today monthly distributions of the following closed-end funds, all with declaration dates of June 1, 2016, ex-dividend dates of June 14, 2016, record dates of June 16, 2016, and payable dates of June 30, 2016:
MFV: 5.55 (unch), CIF: 2.51 (-0.03), CMU: 4.88 (+0.02), MGF: 5.40 (+0.01), MIN: 4.60 (-0.06), MFM: 7.42 (+0.01), MMT: 6.04 (-0.02), CXH: 10.52 (+0.03), CCA: 13.18 (+0.01), CXE: 5.49 (-0.01), MCR: 8.48 (unch)

Board Approves Leverage Refinancing Plan for MFS Municipal Income Trust, MFS Investment Grade Municipal Trust, MFS California Municipal Fund, MFS High Income Municipal Trust, and MFS High Yield Municipal Trust
BusinessWire - Wed Feb 10, 3:15PM CST
MFS Municipal Income Trust (NYSE: MFM), MFS Investment Grade Municipal Trust (NYSE: CXH), MFS California Municipal Fund (NYSE MKT: CCA), MFS High Income Municipal Trust (NYSE: CXE), and MFS High Yield Municipal Trust (NYSE: CMU) today announced that the Board of Trustees of each fund has approved a refinancing plan that is expected to result in the outstanding leverage remaining unchanged for each fund. As part of the refinancing plan, each fund plans to redeem all of its currently outstanding Variable Rate Municipal Term Preferred Shares, Series 2016/9 (the "Series 2016/9 VMTPS" which have a September 2016 maturity date. In addition, each of MFM, CXH, CXE and CMU plan to redeem all of its currently outstanding auction rate municipal preferred shares ("ARPS". The redemption of each fund's respective Series 2016/9 VMTPS and ARPS will be subject to the receipt of financing in the form of new preferred leverage. The Series 2016/9 VMTPS and ARPS will be redeemed at their respective liquidation preferences per share plus additional amounts representing any dividend amounts owed. Taking into account the relatively small amount of ARPS of each fund that remain outstanding following tender offers conducted in 2012, the availability of replacement leverage and other factors, the respective Board of each fund approved the redemption of the remaining ARPS at full liquidation preference as being in the best interests of the fund and its shareholders.
CMU: 4.88 (+0.02), CXH: 10.52 (+0.03), MFM: 7.42 (+0.01), CCA: 13.18 (+0.01), CXE: 5.49 (-0.01)

MFS Closed-End Funds Announce Appointment
BusinessWire - Wed Oct 01, 3:20PM CDT
Robin A. Stelmach has been named president of twelve closed-end funds ("the funds" managed by Massachusetts Financial Services Company, d/b/a MFS Investment Management(R) (MFS(R)), effective today. The twelve funds are:
MFV: 5.55 (unch), CIF: 2.51 (-0.03), CMU: 4.88 (+0.02), MGF: 5.40 (+0.01), MIN: 4.60 (-0.06), CMK: 8.64 (+0.04), MFM: 7.42 (+0.01), MMT: 6.04 (-0.02), CXH: 10.52 (+0.03), CCA: 13.18 (+0.01), CXE: 5.49 (-0.01), MCR: 8.48 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading